Impact of new UNOS allocation criteria on heart transplant practices and outcomes by Liu, Jason et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2021 
Impact of new UNOS allocation criteria on heart transplant 
practices and outcomes 
Jason Liu 
Washington University School of Medicine in St. Louis 
Bin Q. Yang 
Washington University School of Medicine in St. Louis 
Akinobu Itoh 
Washington University School of Medicine in St. Louis 
Mohammed Faraz Masood 
Washington University School of Medicine in St. Louis 
Justin C. Hartupee 
Washington University School of Medicine in St. Louis 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Recommended Citation 
Liu, Jason; Yang, Bin Q.; Itoh, Akinobu; Masood, Mohammed Faraz; Hartupee, Justin C.; and Schilling, Joel 
D., ,"Impact of new UNOS allocation criteria on heart transplant practices and outcomes." Transplantation 
Direct.,. . (2021). 
https://digitalcommons.wustl.edu/open_access_pubs/10018 
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been 
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. 
For more information, please contact engeszer@wustl.edu. 
Authors 
Jason Liu, Bin Q. Yang, Akinobu Itoh, Mohammed Faraz Masood, Justin C. Hartupee, and Joel D. Schilling 







































Transplantation DIRECT         2020 www.transplantationdirect.com 1
ISSN: 2373-8731
Transplantation Direct 2020;6: exxx; doi: 10.1097/TXD.0000000000001088. 
Published online 15  December, , 2020.
Received 4 September 2020. 
Accepted 27 September 2020.
1 Department of Medicine, Division of Cardiology, Barnes-Jewish Hospital/
Washington University School of Medicine, St. Louis, MO.
2 Department of Surgery, Division of Cardiothoracic Surgery, Barnes-Jewish 
Hospital/Washington University School of Medicine, St. Louis, MO.
3 Department of Pathology & Immunology, Washington University School of 
Medicine, St. Louis, MO.
All authors contributed to research design, data collection, and writing of the 
paper. J.L. performed the data analysis.
J.D.S. is a speaker for CareDx. The other authors declare no conflicts of interest.
Correspondence: Joel D. Schilling, MD, PhD, Associate Professor of Medicine, 
Pathology & Immunology, Campus Box 8086, Washington University School of 
Medicine, St. Louis, MO 63110. (schillij@wustl.edu).
Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters 
Kluwer Health, Inc.This is an open-access article distributed under the terms of 
the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 
(CCBY-NC-ND), where it is permissible to download and share the work provided 
it is properly cited. The work cannot be changed in any way or used commercially 
without permission from the journal.
Heart Transplantation
Impact of New UNOS Allocation Criteria on 
Heart Transplant Practices and Outcomes
Jason Liu, MD,1 Bin Q. Yang, MD,1 Akinobu Itoh, MD, PhD,2 Mohammed Faraz Masood, MD,2  
Justin C. Hartupee, MD, PhD,1 and Joel D. Schilling, MD, PhD1,3
INTRODUCTION
In October 2018, the United Network for Organ Sharing 
(UNOS) approved a new heart allocation criteria to prior-
itize the sickest patients with the goal of reducing waitlist 
mortality.1 Changes were made to address the increasing 
number of patients on the transplant waiting list, to better 
account for the severity of illness, and to reflect for an 
increasing population of patients being supported with a 
left ventricular assist device (LVAD).2,3 Notably, the sur-
vival rate of patients supported with LVAD without com-
plications have been improving over the past decade,4 and 
the established guidelines at the time were not reflective of 
these improved outcomes.5
In the new allocation system, the prior 3-tiered system (sta-
tus 1A, 1B, and 2) was changed to a 6-tiered system (Status 
1–6). The current allocation criteria, as outlined in the Organ 
Procurement and Transplantation Network (OPTN) policy, 
are described in Table 1. Status 1A was divided into 3 sepa-
rate categories (status 1, 2, and 3), while status 4 was created 
to correspond to the previous status 1B. As an example, under 
the previous criteria, a patient on venoarterial extracorporeal 
membrane oxygenation (VA-ECMO) and a stable patient on 
LVAD support who is using his or her discretional 30 days of 
Elective 1A time would have the same listing status. However, 
under the new criteria, those patients would instead be listed 
as status 1 and status 3, respectively. This stratification better 
reflects the severity of their illness and prioritizes the patient 
with the greatest chance of death while awaiting transplant. 
Stable patients with durable LVAD support are now listed as 
status 4 under the new allocation criteria instead of status 
1B.6,7 In addition to changes in listing status, a geographical 
range of 500 nautical miles was instituted from the site of the 
donor hospital in an effort to prioritize available organs based 
on illness severity rather than geography.6
Background. In October 2018, a new heart allocation policy was implemented with intent of prioritizing the sickest 
patients and decreasing waitlist time. We examined the effects of the new policy on transplant practices and outcomes 1 
year before and 1 year after the change. Methods. Transplant recipients from October 2017 to September 2019 at our 
institution were identified and divided into 2 cohorts, a preallocation and postallocation criteria change. Patient demograph-
ics, clinical data, and bridging strategy were assessed. Early outcomes including ischemic time, severe primary graft dys-
function, need for renal replacement therapy, and duration of hospital stay were investigated. Results. In the 12 months 
before the change, 38 patients were transplanted as compared to 33 patients in the 12 months after the change. The aver-
age wait-time to transplant decreased after the allocation change (49 versus 313 d, P = 0.02). Patients were more likely to 
be bridged with an intra-aortic balloon pump (45% versus 3%) and less likely to be supported with a durable left ventricular 
assist device (LVAD) after the change (24% versus 82%). There was an increase in total ischemic time after the change (177 
versus 117 min, P ≤ 0.01). There were no significant differences in other early posttransplant outcomes. Conclusions. 
Implementation of the new allocation system for heart transplantation resulted in dramatic changes in the bridging strategy 
utilized at our institution. Temporary mechanical support usage increased following the change and the number of recipients 
supported with durable LVADs decreased. Early posttransplant outcomes appear similar.
(Transplantation Direct 2020;6: e642; doi: 10.1097/TXD.0000000000001088. Published online 15 December, 2020.)
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Preliminary data presented in a 4-month report in April 
2019 published by the OPTN Thoracic Committee demon-
strated no major impact on the number of registrations made 
to the waiting list or the number of transplants performed, 
although it did report a significant increase in ischemic time.8 
Newer data from the UNOS and OPTN registries have 
emerged regarding the effects of the new allocation criteria, 
revealing a shift in bridging strategies and a focus on tempo-
rary mechanical support. The percentage of patients supported 
by LVAD at the time of transplant has decreased significantly, 
whereas those supported by VA-ECMO and intra-aortic bal-
loon pump (IABP) have increased.9-11 While an early analysis 
of the UNOS registry suggested worsening posttransplantation 
outcomes,9 a study of the OPTN registry at the 1-year mark 
did not show significant change observed in either waiting list 
mortality nor posttransplant survival after the policy change 
was instituted.11 However, the effect of the new allocation 
system on the types of temporary mechanical support being 
utilized, trends in clinical care at the institutional level, and 
early outcomes other than mortality is less well understood. 
Therefore, we sought to investigate how the new allocation 
criteria impacted patients transplanted at a single institution 1 
year before and 1 year after the allocation change.
MATERIALS AND METHODS
Study Population
This was a retrospective cohort study that examined 
all adult patients who underwent heart transplantation at 
Barnes-Jewish Hospital/Washington University in St. Louis 
from October 2017 to September 2019. Patients were divided 
into two groups based on if they were transplanted before or 
after October 18, 2018, the date of the allocation change.
Data were gathered through review of electronic medical 
record, including baseline demographics, laboratory values, 
bridging strategy (none, IV inotropes, temporary mechanical 
devices such as IABP or LVAD), patient- and donor-specific 
factors, and early outcomes including the presence of severe 
primary graft dysfunction (PGD), need for renal replace-
ment therapy (RRT) or tracheostomy after transplantation, 
duration of intensive care unit (ICU) stay, and total length of 
hospital stay. Study data were collected and managed using 
REDCap (Research Electronic Data Capture) tools hosted at 
Washington University in St. Louis. REDCap is a secure, web-
based software platform designed to support data capture for 
research studies.12,13
Statistical Analysis
Continuous variables were analyzed using a 2-tailed t-test, 
while categorical variables were analyzed using Chi-square or 
Fisher exact test. A P value <0.05 was considered statistically 
significant. Data analysis was performed using Stata Statistical 
Software (Release 16, College Station, TX). This study was 
reviewed and approved by the Washington University in St. 
Louis Institutional Review Board.
RESULTS
Demographics and Baseline Clinical Data
In total, 71 patients were identified, with 38 patients trans-
planted the year before the change compared to 33 patients 
the year after the change. Baseline characteristics for each 
group are listed in Table  2. Compared with the year prior, 
patients that were transplanted after the allocation change 
had lower serum sodium and hemoglobin and higher total 
bilirubin and hemoglobin A1c. The most common reported 
etiology of heart failure was nonischemic cardiomyopathy 
in both cohorts, 68% (26/38) the year before versus 73% 
(24/33) the year after (P = 0.69). Single organ transplanta-
tion was performed most often, with 95% (36/38) the year 
before versus 97% (32/33) the year after (P = 0.64). While the 
average donor age did not change significantly, the amount 
of organ donations accepted from local organ procurement 
organizations decreased significantly from 97% (37/38) the 
year before to 33% (11/33) the year after (P < 0.01).
Listing Information
The most common listing status before the allocation 
change was status 1B [28/38 (74%)]. Of the 10 patients listed 
as status 1A, 3 were inpatient before the change. One required 
inotropic support, one required IABP support, and the third 
was listed as a 1A exception for ventricular tachycardia. The 
other 7 patients were called in as an outpatient and were 
listed as status 1A exception due to pump malfunction, hem-
orrhagic stroke, hemolysis, aortic insufficiency, or refractory 
GI bleeding. The most common listing status after the allo-
cation change was status 2 [19/33 (60%); Figure 1]. Of the 
TABLE 1.








 Status 1 • VA-ECMO
•  Nondischargeable, surgically implanted, nonendovascular 
biventricular support device
•  MCSD with life-treatening ventricular arrhythmia
Status 1A Status 2 •  IABP
•  Nondischargeable, surgically implanted, nonendovascular 
LVAD
•  VT or VF without mechanical support
•  MCSD with device malfunction or failure
•  TAH, BiVAD, RVAD, or VAD for single ventricle patients
•  Percutaneous endovascular MCSD
 Status 3 •  Dischargeable LVAD for discretionary 30 d
•  Multiple inotropes or single high-dose inotrope with 
continuous hemodynamic monitoring
•  Single inotrope with continuous monitoring
•  VA-ECMO after 7 d; IABP or percutaneous endovascular 
circulatory support device after 14 d
•  Nondischargeable, surgically implanted, nonendovascular 
LVAD after 14 d
•  Mechanical support device with complication
Status 1B Status 4 •  Dischargeable LVAD without discretionary 30 d
•  Inotropes without hemodynamic monitoring
•  Retransplant
•  Diagnosis of CHD, ischemic heart disease with intractable 
angina, hypertrophic CM, restrictive CM, amyloidosis
Status 2 Status 5 •  On waitlist for at least one other organ at the same hospital
 Status 6 •  All other active candidates
The new adult heart allocation criteria and its corresponding status from the previous criteria for 
medical urgency status is adopted from the OPTN website and policies, of which full details can 
be found at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf.
CHD, congenital heart disease; CM, cardiomyopathy; ECMO, venoarterial extracorporeal mem-
brane oxygenation; IABP, intra-aortic balloon pump; (R/L) VAD, (right/left) ventricular assist device; 
TAH, total artificial heart; VA-MCSD, mechanical circulatory support device; VF, ventricular fibril-
lation; VT, ventricular tachycardia.
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19 patients listed as status 2, 15 were supported with IABP, 
while the remaining four patients were listed as status 2 due to 
LVAD malfunction. All status 1 patients were supported with 
ECMO. After the change, there was a statistically significant 
decrease in days spent on the transplant waitlist from 314 to 
49 days (P = 0.02; Table 3).
Shift in Bridging Strategy Utilized
There was a dramatic decrease in patients supported with 
LVAD at the time of transplant, from 82% (31/38) the year 
before the allocation change to 24% (8/33) the year after 
(P < 0.01; Table 3). In contrast, under the new allocation sys-
tem, use of IABP increased from 3% (1/38) to 45% (15/33; 
P < 0.01). There was a suggestion of increased use of 
VA-ECMO (0% versus 9%, P = 0.1); however, other bridging 
strategies such as inotropic support and redo transplantation 
were not statistically different before and after the allocation 
change (Figure 2).
Increasing Use of IABP
The increased use of IABP as a bridging strategy cor-
responded with increased insertion of IABP via the axil-
lary approach after the allocation change (0% versus 68%; 
Table 4). Under the new allocation system, 19 patients in total 
had the use of either femoral or axillary IABP as a bridging 
strategy, with 15 of those able to be transplanted as status 2. 
Of the 4 other patients, 2 received heart transplants after uti-
lization of a different bridging strategy. One required escala-
tion to VA-ECMO and was eventually transplanted as status 
1, and the other experienced bleeding complications neces-
sitating IABP removal and was bridged to transplant on ino-
tropes as a status 3. Further complications necessitating IABP 
exchange or removal are listed in Table 4. During the study 
period under the new allocation criteria, 2 other patients who 
were supported with IABP passed away before transplant due 
to refractory shock. In both cases, LVAD implantation was 
not an option due to severe biventricular dysfunction.
Trends in Clinical Care
After the allocation change, patients were less likely to be 
outpatient at the time of heart transplant. The year before the 
change, 92% (35/38) of patients were called in from home to 
be admitted to the hospital to receive their heart transplant, 
compared with 30% (10/33) the year after. This coincides with 
increased length of stay in the hospital before heart transplant 
after the system change (5 versus 14 d, P = 0.01; Table 5). 
To evaluate how our center adjusted to the new allocation 
system, we assessed transplant volume by quarter over this 
2-years window. As seen in Figure 3, transplant volumes per 
quarter remained consistent until the allocation change, after 
which there was a considerable decrease in the first 2 calen-
dar quarters. Over time, clinical practice was adjusted to align 
with the prioritization scheme of the new system, resulting in 
an increase in transplant volume over the final two quarters 
of the year.
Early Outcomes
A statistically significant increase in cold ischemic time was 
seen under the new system with an average of 177 minutes 
TABLE 2.
Baseline characteristics and clinical data
 
Before allocation 
change (N = 38)
After allocation 
change (N = 33) P
Age (y) 53 54 0.75
Male sex 71% 70% 0.90
Caucasian race 76% 67% 0.37
Body mass index (kg/m2) 29.3 27.5 0.12
Sodium (mEq/L) 139 135 <0.01
Creatinine (mg/dL) 1.4 1.4 0.99
Total bilirubin (mg/dL) 0.7 1.0 0.05
AST (units/L) 37 39 0.72
ALT (units/L) 28 40 0.16
Albumin (g/dL) 4.1 4.0 0.26
Hemoglobin (g/dL) 12.0 11.0 0.02
NT-proBNP (pg/mL) 5734 5645 0.98
Hemoglobin A1c 5.8% 6.4% <0.01
Blood type    
 A 19 13 0.37
 B 2 4 0.41
 O 16 12 0.62
 AB 1 4 0.17
HF etiology    
 Ischemic 10 7 0.62
 NICM 26 24 0.69
 CAVa 2 2 1
Organ transplanted    
 Heart 36 32 0.64
 Heart/kidney 1 1  
 Heart/liver 1 0  
Donor age (y) 27 27 0.80
Local donor 97% 33% <0.01
aTwo patients each in the year before the change as well as the year after had coronary allograft 
vasculopathy, requiring redo orthotopic heart transplantation.
CAV, coronary allograft vasculopathy; NICM, nonischemic cardiomyopathy.
FIGURE 1. Listing status of heart transplants preallocation and postallocation criteria change.
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compared with 117 minutes before the change (P < 0.01; 
Table 5). Otherwise, there were no statistically significant dif-
ferences in any other measured outcomes, including the over-
all number of days intubated, presence of severe PGD, days 
on vasopressor and inotropic support after transplant, use of 
RRT, need for tracheostomy, postoperative infection, treated 
rejection at 6 months, overall ICU length of stay, or length of 
stay in the hospital after heart transplantation. Of note, nearly 
all cases of PGD occurred in patients who went into trans-
plant on LVAD support (Table 5). There was a nonstatistically 
significant increase in posttransplant mortality after the allo-
cation change with 3 patients occurring the year after com-
pared with zero patients the year prior. All 3 deaths occurred 
in patients supported with a durable LVAD.
DISCUSSION
Our study illustrates the profound impact of the new UNOS 
allocation system on transplant practices at a large tertiary 
academic center. Using the 12 months before the implementa-
tion of the system as a control, our data revealed a significant 
decrease in the number of patients transplanted who were 
bridged with a durable LVAD and a simultaneous increase in 
patients who were supported with an IABP. This was associ-
ated with a significant reduction in time on the waitlist before 
transplant. After the change, patients were more likely to be 
hospitalized for several weeks before transplant, and ischemic 
time was increased. However, posttransplant outcomes were 
similar between the cohorts.
Our experience has been compatible with other recent 
analyses demonstrating the shift in bridging strategy fol-
lowing the allocation change. An early investigation of the 
UNOS registry reported that among patients receiving a heart 
FIGURE 2. Bridging strategy before and after the allocation change. Patients transplanted after the heart allocation change were significantly 
more likely to be bridged with an IABP and less likely to be bridged with durable LVAD. IABP, intra-aortic balloon pump; LVAD, left ventricular 
assist device; OHT, orthotopic heart transplant.
TABLE 4.







Patients bridged with IABP 1 19
 Transplanted as status 2 (n, %) 1 (100) 15 (79)
 Transplanted as different statusa 0 2 (11)
 Passed away before transplant 0 2 (11)
Mean days with IABP 6 13
Axillary IABP placement (n, %) 0 13 (68)
Complicationsb (n, %) 0 5 (26)
 Balloon rupture 0 1
 Bacteremia 0 1
 Kinking of catheter shaft 0 1
 Bleeding 0 1
 Limb ischemia 0 1
aTwo patients initially started out with IABP bridging. One required escalation with VA-ECMO and 
was up-listed and eventually transplanted as status 1. The other had IABP removal due to bleed-
ing complication and was transplanted as status 3.
bBalloon rupture and bacteremia required axillary IABP exchange, kinking of the catheter shaft 
required replacement from axillary to femoral positioning, bleeding resulted in IABP removal, limb 
ischemia necessitated thrombectomy and IABP removal.
IABP, intra-aortic balloon pump; VA-ECMO, venoarterial extracorporeal membrane oxygenation.
TABLE 3.
Transplant listing data, including bridging strategy utilized 
before and after heart allocation change
 
Before allocation  
change (N = 38)
After allocation  
change (N = 33) P
Days on transplant list 314 49 0.02
Called in as outpatienta (n, %) 35 (92) 10 (30) <0.01
Bridging strategy (n, %)    
 VAD 31 (82) 8 (24) <0.01
  HM2 15 2  
  HM3 8 1  
  HVAD 8 5  
 IABP 1 (3) 15 (45) <0.01
 Inotropic support 3 (8) 5 (15) 0.46
 VA-ECMO 0 (0) 3 (9) 0.10
 Redo OHT 2 (5) 2 (6) 1
 Noneb 1 (3) 0 (0) 1
aPatients who were called in to the hospital while outpatient for admission to receive their heart 
transplant were listed as such, compared to patients that were already hospitalized for decom-
pensated heart failure when they received their transplant.
bOne patient was admitted with multiple shocks from an implanted cardiac defibrillator and was 
listed as a status 1A exception for ventricular tachycardia. This patient went into PEA arrest after 
attempted defibrillation threshold testing and stayed in the hospital over 3 mo before transplant. 
The patient did not receive inotropic support or mechanical device support at any time during 
the hospitalization.
HM2, HeartMate 2; HM3, HeartMate 3; HVAD, HeartWare VAD; IABP, intra-aortic balloon pump; 
OHT, orthotopic heart transplant; VA-ECMO, venoarterial extracorporeal membrane oxygenation; 
VAD, ventricular assist device.
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transplant those bridged with LVADs decreased from 42% to 
23%, while those bridged with temporary mechanical sup-
port increased from 10% to 41% after the allocation change.9 
Another recent study by Varshney et al14 demonstrated a 
significant increase in temporary mechanical circulatory 
support (MCS) among patients with acute decompensated 
heart failure in the US transplant centers. At our institution, 
the use of IABP as a bridging strategy increased significantly 
from 3% to 45% after the allocation change. Furthermore, 
68% of patients who received IABP had the device placed in 
the axillary position, which has been shown to represent a 
well-tolerated bridging strategy.15 IABP complications neces-
sitating removal or exchange occurred in 26% of cases at 
our center. These results are comparable to recent study by 
Bhimaraj et al,16 who reported that in a large series of patients 
with axillary IABP insertion that 15.8% required at least one 
IABP replacement. Two other reviews have suggested vascu-
lar complication rates of 8%–18%17 and 0.94%–31.1%.18 In 
our series, 79% of IABP bridged patients successfully made 
it to transplant, further supporting the concept that this is an 
acceptable strategy to bridge patients to transplant. In com-
parison, other studies have shown rates of ~70% success in 
bridging patients with axillary IABP support to transplant or 
LVAD.16 Similar findings have also been reported using the 
Impella 5.0 as a bridge to durable MCS or heart transplant.19
Another striking observation was that the lower priority 
assigned to those on LVAD support (status 4) has resulted in 
fewer of these patients receiving a heart transplant, a find-
ing echoed in recent analyses of the UNOS9 and OPTN10,11 
registries. At our institution, only 3 patients (9%) were trans-
planted from a status 4 listing under the new allocation cri-
teria. The other 5 patients on durable LVAD support were 
up-listed due to complications related to their LVAD. The 
combination of a lower listing status along with an increase 
in geographic range for available donors has led to decreased 
offers for status 4 patients when compared with status 1B 
patients the year prior. Thus, the new system has increased 
TABLE 5.
Early outcomes after heart transplantation
 
Before allocation 
change (N = 38)
After allocation 
change (N = 33) P
Ischemic time (min) 117 177 <0.01
Days intubated 3 3 0.82
Days in ICU 7 9 0.33
Days in hospital before OHT 5 14 0.01
Days in hospital after OHT 7 9 0.33
Severe PGD (n, %) 6 (16) 5 (15) 1
 PGD patients with LVAD 6 (100) 4 (80) 0.12
 % LVAD patients with PGD 19% 50% 0.19
Days on vasopressors/inotropes 8 7  
vasopressors >7 d (n, %) 16 (42) 9 (27)  
Usage of RRT (n, %) 12 (32) 14 (42) 0.34
Tracheostomy (n, %) 4 (11) 6 (18) 0.50
Infection (n, %) 8 (21) 9 (27) 0.54
Treated rejection (n,%) 8 (21) 3 (9) 0.16
Expired (n, %) 0 (0) 3 (9) 0.10
ICU, intensive care unit; OHT, orthotopic heart transplant; PGD, primary graft dysfunction; RRT, 
renal replacement therapy.
FIGURE 3. Transplant volume by calendar quarter. Transplant volume was lowest in the two quarters immediately following the allocation 
change on October 18, 2018. ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; OHT, orthotopic heart transplant; 
VAD, ventricular assist device.
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wait times for those who are doing well on LVAD support. 
This has created a system of practice where durable MCS 
and transplant are effectively parallel pathways rather than 
events in series. Although there may be some advantages to 
this approach moving forward, it has disadvantaged many 
LVAD patients who were implanted as a bridge to trans-
plant before the allocation change. In addition, the practice 
of only transplanting LVAD patients with complications has 
the potential to worsen both short-term and long-term trans-
plant outcomes.
There have been concerns in the transplant community that 
the changes in the new allocation policy designed to reduce 
death on the waitlist could worsen posttransplant outcomes. 
In particular, the combination of increased allograft ischemic 
time and more severe illness in recipients has been considered a 
recipe for early complications such as PGD. Although an early 
analysis of the UNOS registry reported by Cogswell et al9 found 
a significant increase in post-heart transplant death in the new 
system, analysis of the OPTN data by Goff et al11 did not show 
significant change in posttransplant survival at the 1-year mark. 
Similar to other studies,8,9,11 we observed a significant increase 
in ischemic time under the new allocation system. This was 
likely a result of a significant increase in accepted organs from 
outside our local organ procurement organization. However, 
despite the longer ischemic time and increased use of temporary 
support, we did not observe significant differences in the use of 
RRT, tracheostomy, length of stay in the ICU, length of stay in 
the hospital, or severe PGD after transplant. In fact, 91% of the 
severe PGD occurred in those with LVADs in both years of this 
study. This observation is in line with prior data that LVADs 
are a major risk factor for PGD.20 A concerning finding is that 
under the new system severe PGD occurred in 50% of patients 
who had an LVAD going into transplant. This may be a conse-
quence of the new system favoring organ allocation to LVAD 
patients with complications. To this point, we recently demon-
strated that patients with the right heart failure on LVAD sup-
port are at higher risk of PGD posttransplant compared with 
stable patients on LVAD support.21
Although our study was too small to address mortal-
ity concerns, there were 3 patients who expired the year 
after the change. All of these patients were supported with 
LVADs and the cause of death was attributable to compli-
cations of severe PGD. At the time of this reporting, there 
were no further deaths among patients transplanted in the 
year after the allocation change. Thus, we conclude that 
increased use of temporary support devices and longer 
ischemic times did not worsen early posttransplant out-
comes at our institution. Rather, the mortality observed in 
our study was seen only in patients supported with LVADs. 
Further investigation of these relationships in larger patient 
series’ with longer follow-up will be necessary to delineate 
the implications of the allocation change on early and late 
posttransplant outcomes.
LIMITATIONS
First, this a single-center study with a limited sample size, 
and the results cannot necessarily be generalized to clinical 
practice at other institutions. However, over the study period, 
all heart transplants were evaluated by the same groups of 
advanced heart failure physicians and cardiac surgeons at our 
institution. Next, this study was performed at the 1-year mark 
of allocation change, and only short-term outcomes were 
available. Finally, this study was not large enough to address 
the increasing use of VA-ECMO. At our institution, 9% of 
patients were bridged with VA-ECMO successfully; however, 
this approach must be used carefully.22
CONCLUSION
Implementation of the new heart allocation system at our 
institution resulted in dramatic changes in utilization of the 
bridging strategy for transplantation. Patients were less likely 
to be supported with durable LVADs and were more likely to 
be supported by IABP after the allocation change, resulting in 
decreased days on the waitlist and increased inpatient hospital 
length of stay before the transplant. Early posttransplant out-
comes appear similar. Further monitoring of posttransplant 
outcomes will be needed to evaluate the longer-term effects of 
the allocation criteria changes.
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